H.C. Wainwright Starts Stemline Therapeutics (STML) at Buy

H.C. Wainwright initiated coverage on Stemline Therapeutics (NASDAQ: STML) with a Buy rating and a price target of $38.00.

Analyst Yi Chen said, "In our view, Stemline represents a unique investment opportunity in the small-cap oncology space due to its rapidly advancing clinical-stage pipeline and the proprietary development platform in cancer stem cells (CSCs)."

"We believe that Stemline could potentially secure regulatory approval with SL-401 in BPDCN in late 2017. SL-401 may subsequently gain approval in additional niche blood cancer indications in which the drug is being tested. This drug may have potential in other broader indications such as acute myeloid leukemia (AML) and myeloma. Stemline’s second pipeline candidate SL-701, an immunotherapy, could potentially gain approval in adult and pediatric glioma in the 2018-2019 time frame, in our view, for which it has gained the orphan drug designation from the FDA in January 2015. In our view, Stemline is one of the most attractive development-stage oncology-focused firms, given its potential for an accelerated path to market for niche indications, and its technology and pipeline targeting CSCs," added the analyst.

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.

Shares of Stemline Therapeutics closed at $16.58 yesterday.

You May Also Be Interested In

• BofA Securities Starts Madrigal Pharmaceuticals (MDGL) at Underperform, 'pivoting to Rezdiffra commercial dynamics'
• BofA Securities Reinstates Gujarat Gas Ltd (GUJGA:IN) at Underperform
• Ambit Capital Starts Tata Technologies (TATATECH:IN) at Sell (4)